Real-time contrast-enhanced ultrasound-guided percutaneous biopsy in the diagnosis of ovarian metastasis of gallbladder carcinoma: a case report
Tóm tắt
Multiple-organ primary tumors can invade the ovary through lymphatic and hematogenous routes, presenting as ovarian Krukenberg tumors, but these rarely originate from the gallbladder. Krukenberg tumors can present similar to primary ovarian tumors; however, their treatments are completely different. A 62-year-old Chinese woman presented with abdominal distension for six months and weight loss of five kilograms for two months. Based on multiple imaging examinations, the patient was preliminarily diagnosed with a malignant tumor of unknown origin with multiple metastases (omentum). To identify the origin of the malignancy, the patient underwent real-time contrast-enhanced ultrasound-guided percutaneous biopsy. The results revealed a perihepatic hypoechoic lesion and right adnexal mass that were both metastatic adenocarcinomas from the gallbladder. The patient initially received chemotherapy with gemcitabine and cisplatin instead of surgery. However, the tumor increased in size on re-examination after two cycles, so the treatment was shifted to a combination regimen with durvalumab for six cycles. The treatment proceeded smoothly, with no recurrence or obvious progression of the cancer during follow-up. Differentiating between primary and metastatic ovarian tumors is important. Early diagnosis and effective treatment options are essential for patient survival. CEUS-guided percutaneous biopsy is a valuable procedure for patients with multiple metastases who cannot tolerate surgery.
Tài liệu tham khảo
Kubeček O, Laco J, Špaček J, et al. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clin Exp Metastasis. 2017;34(5):295–307.
Roseland ME, Millet JD, Wasnik AP. Imaging of metastatic disease to the Ovary/Adnexa. Magn Reson Imaging Clin N Am. 2023;31(1):93–107.
Ghahremani P, Li Y, Kaufman A, et al. Deep learning-inferred multiplex ImmunoFluorescence for immunohistochemical image quantification. Nat Mach Intell. 2022;4(4):401–12.
Ajani MA, Iyapo O, Salami A, Okolo CA. SECONDARY OVARIAN NEOPLASMS IN A TERTIARY HOSPITAL IN SOUTHWESTERN NIGERIA. Ann Ib Postgrad Med. 2019;17(1):19–23.
Alvarado-Cabrero I, Rodríguez-Gómez A, Castelan-Pedraza J, Valencia-Cedillo R. Metastatic ovarian tumors: a clinicopathologic study of 150 cases. Anal Quant Cytopathol Histpathol. 2013;35(5):241–8.
Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics. Gynecol Oncol. 2006;101(1):97–101.
Lionetti R, DE Luca M, Raffone A, et al. Clinics and pathology of Krukenberg tumor: a systematic review and meta-analysis. Minerva Obstet Gynecol. 2022;74(4):356–63.
Agnes A, Biondi A, Ricci R, Gallotta V, D’Ugo D, Persiani R. Krukenberg tumors: seed, route and soil. Surg Oncol. 2017;26(4):438–45.
Sal V, Demirkiran F, Topuz S, et al. Surgical Treatment of metastatic ovarian tumors from Extragenital Primary Sites. Int J Gynecol Cancer. 2016;26(4):688–96.
Karaosmanoglu AD, Onur MR, Salman MC, et al. Imaging in secondary tumors of the ovary. Abdom Radiol (NY). 2019;44(4):1493–505.
Guo Z, Shi H, Li W, et al. Chinese multidisciplinary expert consensus: guidelines on percutaneous transthoracic needle biopsy. Thorac Cancer. 2018;9(11):1530–43.
Wu W, Jing X, Xue GQ, et al. A Multicenter Randomized controlled study of contrast-enhanced US versus US-guided Biopsy of Focal Liver Lesions. Radiology. 2022;305(3):721–8.
Huang JX, Shi CG, Xu YF, et al. The benefit of contrast-enhanced ultrasound in biopsies for focal liver lesions: a retrospective study of 820 cases. Eur Radiol. 2022;32(10):6830–9.
Al-Agha OM, Nicastri AD. An in-depth look at Krukenberg tumor: an overview. Arch Pathol Lab Med. 2006;130(11):1725–30.
Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24(6):751–64.
Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–8.